Additionally, CA125/MUC16 bound to newer antibody-based lymphoma treatment agents, including obinutuzumab and tafasitamab, suppressing their immune effector functions. Bispecific antibodies mosunetuzumab and glofitamab also exhibited reduced cytotoxicity in the presence of CA125/MUC16. These findings suggest that NAV-006 could improve therapeutic efficacy in B-cell lymphomas, particularly in patients with elevated CA125/MUC16 levels.

5 months ago

Preclinical • Journal

MUC16 (Mucin 16, Cell Surface Associated)

Rituxan (rituximab) • Gazyva (obinutuzumab) • Monjuvi (tafasitamab-cxix) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • NAV-006

4years

Block-Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression. (PubMed, Oncol Lett)

Rituximab (RTX) is a CD20-targeting antibody that is the standard-of-care for patients with non-Hodgkin Lymphoma (NHL) cases. Furthermore, the study characterized an RTX variant, named NAV-006 (RTX-N109D), which was more refractory to the immunosuppressive effects mediated by CA125 as evidenced by its reduced CA125 interaction and increased activity of ADCC and CDC when compared with parent RTX. Taken together, these findings warranted further investigation on NAV-006 as a next generation anti-CD20 antibody that could improve the efficacy of parent RTX in NHL patients with high levels of CA125.

4 years ago

Journal

MUC16 (Mucin 16, Cell Surface Associated)

Rituxan (rituximab) • NAV-006